Baxalta Belgium Manufacturing SA – FDA 483, May 20, 2019
An FDA inspection of Baxalta Belgium Manufacturing S.A. in Lessines, Belgium, a licensed biological manufacturer, revealed significant deficiencies across multiple areas. Observations included inadequate computer system validation and batch review processes, leading to product quality issues like endotoxin trends and visible particulates. The firm also failed to timely report biological product deviations and serious unexpected adverse events, and did not conduct adequate quality investigations for reported viral transmission and fungal infection events. Additionally, facility design was found to be inappropriate for cleaning and maintenance.
ID · 6dbcde81-2291-4b42-a556-6dc3897f5b55
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.